Qmes brings quantum sensing, computing, and imaging into healthcare—enabling earlier detection, faster research, and more precise medical insights.
Detect biochemical signals at unprecedented sensitivity — enabling early detection of cancer, infections, neurodegenerative disorders, and metabolic abnormalities.
Simulate complex molecular structures and reactions with higher precision, reduce R&D cycles, and increase the success rate of therapeutic discovery.
Quantum-enhanced MRI and MEG deliver higher resolution with lower noise — reducing reliance on contrast agents and minimizing radiation exposure.
Ultra-sensitive Biosensing
85%
Hybrid QC Algorithms
75%
We address key questions from partners and investors regarding the application, integration, and security of quantum technology in preventive healthcare.
Quantum technology is not a mere buzzword; it is a technical necessity for overcoming critical limitations in modern medicine. Preventive healthcare demands ultra-early, high-sensitivity detection and the precise simulation of complex biomolecules, which current technologies struggle with:
Detection Limits: Traditional sensors lack the sensitivity to capture trace amounts of early-stage biomarkers. Quantum sensors (like NV-centers or SQUIDs) can detect magnetic or electrical signals in the picotesla or even femtotesla range, allowing for disease signals to be potentially identified years in advance.
Computational Bottleneck: Conventional supercomputers struggle to accurately simulate complex molecules exceeding 50 to 70 electrons, severely slowing down drug research. Quantum computing breaks this barrier, enabling high-fidelity molecular simulation necessary for R&D acceleration.
Our core difference lies in transcending the limits of classical physics across three domains:
Ultra-Sensitivity: Our Quantum Sensing components achieve sensitivity levels previously impossible, enabling the detection of markers that are simply invisible to traditional diagnostics, leading to truly earlier screening.
Precision Simulation: Our Quantum Computing platform enables highly accurate virtual screening and molecular optimization, which significantly reduces R&D cycles and increases the success rate of therapeutic discovery compared to approximate classical methods.
Enhanced Safety & Resolution: Our Quantum Imaging components leverage quantum principles to achieve a higher signal-to-noise ratio and better resolution, reducing the need for contrast agents and minimizing patient exposure to radiation.
No, dedicated, in-house quantum hardware is not necessarily required.
Hybrid Architecture: Our core strength is our Hybrid Classical–Quantum Architecture. We run the majority of standard workloads (data pre-processing, classic optimization) on established High-Performance Computing (HPC) platforms.
On-Demand Quantum: Quantum resources are primarily accessed via the cloud and reserved only for high-value, complex tasks such as finding the molecular ground state or solving massive optimization problems.
Cost Efficiency: This model ensures deployment flexibility, minimal capital expenditure, and an optimized cost-per-result model, making quantum advantages immediately accessible and cost-effective for our partners.
Our technology platform is highly versatile and is currently focused on the following high-impact areas:
Early Disease Screening: Utilizing quantum sensors for the detection of circulating tumor DNA (ctDNA), neurodegenerative markers, and trace metabolic signals.
Drug and Vaccine R&D Acceleration: Assisting drug discovery teams with high-accuracy virtual screening, conformational analysis, and de novo design, accelerating the path to new therapies.
Precision Medical Imaging: Utilizing quantum-enhanced components to improve the spatial and temporal resolution of MRI and MEG devices, enabling more detailed and safer diagnostics.
Public Health & Data Security: Employing quantum-safe cryptographic protocols in clinical data sharing and federated learning to guarantee unparalleled patient data privacy and long-term regulatory compliance.
We follow a structured, three-phase collaboration model designed for smooth translation from research to clinical reality:
Research Phase: Initiate Proof-of-Concept (PoC) projects to jointly validate the feasibility and advantage of a specific quantum technology in the partner’s application scenario.
Pilot Phase: Translate the successful PoC into a functional prototype or service platform, and conduct real-world testing and validation in the partner’s clinical or laboratory environment.
Commercialization Phase: Upon successful validation, assist with standardization, regulatory compliance, and launch the scalable and commercially viable quantum-enhanced device or service platform.
© COPYRIGHT 2025 QMESH TECHNOLOGIES INC reg no : 00000000 ( 000000-K ) | ALL RIGHTS RESERVED | DEVELOP BY IONIA ENTERPRISE.